4D pharma plc Warrant (LBPSW)
$0.04
$-0.02
(-25.71%)
As on 29-Jun-2022 09:57EDT
Market cap
--
Revenue (TTM)
--
P/E Ratio
--
P/B Ratio
--
Div. Yield
--
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
--
-
ROE
--
-
ROCE
--
-
Industry P/E
--
-
EV/EBITDA
--
-
Debt to Equity
--
-
Book Value
--
-
EPS
--
-
Face value
--
-
Shares outstanding
--
5 Years Aggregate
CFO
£-109.44 Mln
EBITDA
£-162.25 Mln
Net Profit
£-148.12 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
4D pharma plc Warrant (LBPSW)
| -91.8 | -84.9 | -88.7 | -95.8 | -- | -- | -- |
|
BSE Sensex*
| -8.8 | 0.6 | 1.8 | -4.4 | 6.0 | 6.6 | 10.8 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Shareholding Pattern
View DetailsAbout 4D pharma plc Warrant (LBPSW)
4D pharma plc, together with its subsidiaries, engages in the research, development, and production of live biotherapeutic products. The company develops therapeutic candidates, such as MRx0518; MRx-4DP000 for the treatment of asthma and COVID-19;... MRx0029 the treatment of central nervous system disorders; Blautix for irritable bowel syndrome; and Thetanix for pediatric crohn's disease. It also develops products candidates, including MRx1299 for solid tumors, MRx0005 for neurodegeneration, MRx0006 for rheumatoid arthritis, and MRx0002 for multiple sclerosis. The company develops MicroRx platform to discover new LBP candidates for major diseases. 4D pharma plc has a collaboration agreement with Merck & Co., Inc. to conduct a clinical trial evaluating the combination of Keytruda and MRx0518 in patients with solid tumors. The company was formerly known as Schosween 18 Limited. 4D pharma plc was incorporated in 2014 and is headquartered in Leeds, the United Kingdom. Read more
-
CEO & Exec. Director
Mr. Duncan Joseph Peyton
-
CEO & Exec. Director
Mr. Duncan Joseph Peyton
-
Headquarters
Leeds
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for 4D pharma plc Warrant (LBPSW)
What is the current share price of 4D pharma plc Warrant (LBPSW) Today?
The share price of 4D pharma plc Warrant (LBPSW) is $0.04 (NASDAQ) as of 29-Jun-2022 09:57 EDT. 4D pharma plc Warrant (LBPSW) has given a return of -95.75% in the last 1 years.
What is the current PB & PE ratio of 4D pharma plc Warrant (LBPSW)?
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2021 |
-1.31 |
3.05 |
2020 |
-- |
-- |
2019 |
-- |
-- |
2018 |
-- |
-- |
2017 |
-- |
-- |
What is the 52 Week High and Low of 4D pharma plc Warrant (LBPSW)?
The 52-week high and low of 4D pharma plc Warrant (LBPSW) are Rs -- and Rs -- as of 29-Aug-2026.
What is the market cap of 4D pharma plc Warrant (LBPSW)?
4D pharma plc Warrant (LBPSW) has a market capitalisation of $ 188 Mln as on 29-Jun-2022. As per SEBI classification, it is a company.
Should I invest in 4D pharma plc Warrant (LBPSW)?
Before investing in 4D pharma plc Warrant (LBPSW), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.